富光制药将收购的 Union Korea Pharm 更名为 Bukwang Unipharma，推进业务重组

Bukwang Pharmaceutical Renames Acquired Union Korea Pharm as Bukwang Unipharma - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
A view of Bukwang Pharmaceutical's headquarters. Photo courtesy of Bukwang Pharmaceutical
Union Korea Pharm, acquired by Bukwang Pharmaceutical (003000), will change its name to Bukwang Unipharma and accelerate a realignment of its business. Bukwang Pharmaceutical plans to expand its portfolio by tapping production capabilities it did not previously have, including Union Korea Pharm's antibiotic and injectable drug operations.
Union Korea Pharm (080720) held an extraordinary shareholders meeting on the 8th at its headquarters in Wonju, Gangwon State, where shareholders approved a partial amendment to the company's articles of incorporation to allow the name change. The corporate name was changed to Bukwang Unipharma Co. Shareholders also approved the appointment of an auditor and compensation limits for directors and auditors.
The name change is a follow-up step in restructuring the business after the acquisition by Bukwang Pharmaceutical. Bukwang was selected as the preferred bidder for Union Korea Pharm, which was undergoing court-led rehabilitation, and completed the acquisition after the court approved the rehabilitation plan. Bukwang Unipharma has now exited rehabilitation proceedings.
Bukwang Pharmaceutical aims to secure a stable production base by linking its existing prescription drug business with Bukwang Unipharma's manufacturing facilities. It will broaden its production range into antibiotics and injectables while also expanding its product portfolio and seeking new business opportunities.
"We will carry out the remaining steps without disruption to complete the normalization of management as soon as possible, and we will effectively combine the capabilities of both companies to strengthen production competitiveness and business synergy," an official at Bukwang Pharmaceutical said.
#
BukwangPharmaceutical
#
BukwangUnipharma
#
UnionKoreaPharm
#
Pharma
#
MergersAndAcquisitions
#
KoreaStocks
Original reporting by
Lee Yeon-soo
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:43
After the Fed's Rate Hike, Rethink Your Stock Portfolio
2:43
Most Read This Week
1
-
5
‹
›
1
Military Exemption Boasts Spark Push to Overhaul Athlete Rules
2
AMRO Lifts Korea's 2026 Growth Forecast Again to 3.3%
3
U.S. Private Colleges Slash Tuition as Applicants Walk Away
4
China's TCL Passes Samsung in LCD TVs, Leads by 0.1 Point
5
42dot Hires Three Global Tech Leaders to Boost SDV Capabilities
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗